CN101778850A - 杂芳基酰胺类似物 - Google Patents

杂芳基酰胺类似物 Download PDF

Info

Publication number
CN101778850A
CN101778850A CN200880021498A CN200880021498A CN101778850A CN 101778850 A CN101778850 A CN 101778850A CN 200880021498 A CN200880021498 A CN 200880021498A CN 200880021498 A CN200880021498 A CN 200880021498A CN 101778850 A CN101778850 A CN 101778850A
Authority
CN
China
Prior art keywords
alkyl
base
pyrimidine
chloro
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880021498A
Other languages
English (en)
Chinese (zh)
Inventor
R·巴克塔瓦查拉姆
D·C·伊尔
S·M·卡皮托斯蒂
D·J·武斯特罗
J·原
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of CN101778850A publication Critical patent/CN101778850A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN200880021498A 2007-08-10 2008-08-11 杂芳基酰胺类似物 Pending CN101778850A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95525007P 2007-08-10 2007-08-10
US60/955,250 2007-08-10
PCT/US2008/072760 WO2009023623A1 (en) 2007-08-10 2008-08-11 Heteroaryl amide analogues

Publications (1)

Publication Number Publication Date
CN101778850A true CN101778850A (zh) 2010-07-14

Family

ID=40351102

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880021498A Pending CN101778850A (zh) 2007-08-10 2008-08-11 杂芳基酰胺类似物

Country Status (14)

Country Link
EP (1) EP2185560A4 (pt)
JP (2) JP2010535816A (pt)
KR (1) KR20100066422A (pt)
CN (1) CN101778850A (pt)
AU (1) AU2008286946B2 (pt)
BR (1) BRPI0812594A2 (pt)
CA (1) CA2691512A1 (pt)
CO (1) CO6251319A2 (pt)
EA (1) EA020332B1 (pt)
IL (1) IL202550A0 (pt)
NZ (1) NZ582056A (pt)
SG (1) SG183699A1 (pt)
UA (1) UA99729C2 (pt)
WO (1) WO2009023623A1 (pt)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104854087A (zh) * 2012-12-18 2015-08-19 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的吲哚羧酰胺衍生物
CN104918946A (zh) * 2013-01-22 2015-09-16 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的杂环酰胺衍生物
CN105209464A (zh) * 2013-03-14 2015-12-30 詹森药业有限公司 P2x7调节剂
CN105636646A (zh) * 2013-07-17 2016-06-01 全球结核病药物研发联盟 氮杂吲哚化合物、其合成及其使用方法
US9540388B2 (en) 2013-03-14 2017-01-10 Janssen Pharmaceutica Nv P2X7 modulators
CN106478662A (zh) * 2012-07-17 2017-03-08 武田药品工业株式会社 5‑ht3受体拮抗剂
US9604982B2 (en) 2013-03-14 2017-03-28 Janssen Pharmaceutica Nv P2X7 modulators
US10047092B2 (en) 2013-03-14 2018-08-14 Janssen Pharmaceutica Nv Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
US10150766B2 (en) 2014-09-12 2018-12-11 Janssen Pharmaceutica Nv P2X7 modulators
US10329306B2 (en) 2014-09-29 2019-06-25 Takeda Pharmaceutical Company Limited Crystalline form of 1-(1-methyl-1H-pyrazol-4-yl)-N-((IR,5S,7S)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1H-indole-3-carboxamide
WO2022062991A1 (zh) * 2020-09-22 2022-03-31 苏州恩华生物医药科技有限公司 吲哚衍生物及其应用
US11597728B2 (en) 2018-09-28 2023-03-07 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
WO2023198199A1 (zh) * 2022-04-15 2023-10-19 先声再明医药有限公司 膜缔合酪氨酸和苏氨酸激酶抑制剂
US11820766B2 (en) 2018-09-28 2023-11-21 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
US11839663B2 (en) 2019-09-30 2023-12-12 Janssen Pharmaceutica Nv Radiolabelled MGL pet ligands
US11891387B2 (en) 2020-03-26 2024-02-06 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011010810A (es) * 2009-04-14 2012-01-12 Affectis Pharmaceuticals Ag Nuevos antagonistas de p2x7r y su uso.
WO2012110190A1 (en) * 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
JP6208122B2 (ja) 2011-05-12 2017-10-04 プロテオステイシス セラピューティクス，インコーポレイテッド プロテオスタシス調節因子
WO2012163792A1 (en) * 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) * 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2013014587A1 (en) 2011-07-22 2013-01-31 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
EA024204B1 (ru) * 2012-01-20 2016-08-31 Актелион Фармасьютиклз Лтд. Производные гетероциклических амидов в качестве антагонистов p2xрецептора
EA029644B1 (ru) * 2012-12-12 2018-04-30 Идорсиа Фармасьютиклз Лтд Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов
ES2616114T3 (es) 2013-01-22 2017-06-09 Actelion Pharmaceuticals Ltd. Derivados de amida heterocíclica como antagonistas del receptor P2X7
PE20151332A1 (es) 2013-02-19 2015-09-20 Pfizer Compuestos de azabencimidazol
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
DK3177624T3 (da) 2014-08-06 2019-07-01 Pfizer Imidazopyridazinforbindelser
WO2016100281A1 (en) * 2014-12-15 2016-06-23 Merck Patent Gmbh Indole and azaindoles derivatives and their use in neurodegenerative diseases
JP6462493B2 (ja) 2015-05-29 2019-01-30 株式会社デンソー 進入判定装置、進入判定方法
CA3010615C (en) 2016-01-14 2024-02-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
TW201819361A (zh) 2016-09-03 2018-06-01 印度商托仁特生技有限公司 新穎吲唑化合物

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4374846A (en) * 1979-08-02 1983-02-22 Kali-Chemie Pharma Gmbh N-Amino alkyl indole compounds compositions containing same, and a method of using same in therapy of disorders of gastrointestinal motility
US4803198A (en) * 1981-08-08 1989-02-07 Kali-Chemie Pharma Gmbh 1-Phenyl-2-aminocarbonylindole compounds, preparation thereof and pharmaceutical compositions containing them
CN1082318A (zh) * 1992-06-05 1994-02-23 国际壳牌研究有限公司 杀真菌的吲哚衍生物
US5424329A (en) * 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion
CN1353702A (zh) * 1999-04-09 2002-06-12 阿斯特拉曾尼卡有限公司 金刚烷衍生物
US20030203909A1 (en) * 2000-08-09 2003-10-30 Hiroyuki Ushio Fused bicyclic amide compounds and medicinal use thereof
WO2004056768A2 (en) * 2002-12-20 2004-07-08 Bayer Healthcare Ag Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
US20050020593A1 (en) * 2003-07-24 2005-01-27 Aventis Pharma Aryl-heteroaromatic compounds, compositions comprising them and use
CN1589270A (zh) * 2001-11-22 2005-03-02 安万特医药德国有限公司 作为因子Xa抑制剂的吲哚－2－甲酰胺化合物
US20050165049A1 (en) * 2004-01-23 2005-07-28 Christopher Hulme Vanilloid receptor ligands and their use in treatments
CN101010297A (zh) * 2004-08-05 2007-08-01 赛诺菲-安万特 N－(1h－吲哚基)－1h－吲哚－2－羧酰胺衍生物，它们的制备方法和药用用途
CN101115718A (zh) * 2005-01-07 2008-01-30 赛诺菲-安万特 N-(杂芳基)-1h-吲哚-2-甲酰胺衍生物及其作为辣椒素trpv1受体配位体的用途
CN101151246A (zh) * 2005-03-21 2008-03-26 欧加农股份有限公司 1-苄基吲哚-2-甲酰胺衍生物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2557342A1 (de) * 1975-12-19 1977-06-30 Hoechst Ag Basisch substituierte indolderivate und verfahren zu ihrer herstellung
US5023265A (en) * 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
KR100608472B1 (ko) * 1997-12-24 2006-08-09 사노피-아벤티스 도이칠란트 게엠베하 인자 Ｘａ의 억제제로서의 인돌 유도체 및 이를 함유하는 약제학적 조성물
WO2001025220A1 (en) * 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
CA2399791A1 (en) * 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
JP4529119B2 (ja) * 2001-08-09 2010-08-25 小野薬品工業株式会社 カルボン酸誘導体化合物およびその化合物を有効成分として含有する薬剤
ES2293005T3 (es) * 2002-10-03 2008-03-16 F. Hoffmann-La Roche Ag Indol-3-carboxamidas como activadores de la glucocinasa.
DE10253426B4 (de) * 2002-11-15 2005-09-22 Elbion Ag Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
FR2888847B1 (fr) * 2005-07-22 2007-08-31 Sanofi Aventis Sa Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
WO2007079239A2 (en) * 2005-12-30 2007-07-12 Acadia Pharmaceuticals Inc. Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof
AU2007217474A1 (en) * 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4374846A (en) * 1979-08-02 1983-02-22 Kali-Chemie Pharma Gmbh N-Amino alkyl indole compounds compositions containing same, and a method of using same in therapy of disorders of gastrointestinal motility
US4803198A (en) * 1981-08-08 1989-02-07 Kali-Chemie Pharma Gmbh 1-Phenyl-2-aminocarbonylindole compounds, preparation thereof and pharmaceutical compositions containing them
CN1082318A (zh) * 1992-06-05 1994-02-23 国际壳牌研究有限公司 杀真菌的吲哚衍生物
US5424329A (en) * 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion
CN1353702A (zh) * 1999-04-09 2002-06-12 阿斯特拉曾尼卡有限公司 金刚烷衍生物
US20030203909A1 (en) * 2000-08-09 2003-10-30 Hiroyuki Ushio Fused bicyclic amide compounds and medicinal use thereof
CN1589270A (zh) * 2001-11-22 2005-03-02 安万特医药德国有限公司 作为因子Xa抑制剂的吲哚－2－甲酰胺化合物
WO2004056768A2 (en) * 2002-12-20 2004-07-08 Bayer Healthcare Ag Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
US20050020593A1 (en) * 2003-07-24 2005-01-27 Aventis Pharma Aryl-heteroaromatic compounds, compositions comprising them and use
US20050165049A1 (en) * 2004-01-23 2005-07-28 Christopher Hulme Vanilloid receptor ligands and their use in treatments
CN101010297A (zh) * 2004-08-05 2007-08-01 赛诺菲-安万特 N－(1h－吲哚基)－1h－吲哚－2－羧酰胺衍生物，它们的制备方法和药用用途
CN101115718A (zh) * 2005-01-07 2008-01-30 赛诺菲-安万特 N-(杂芳基)-1h-吲哚-2-甲酰胺衍生物及其作为辣椒素trpv1受体配位体的用途
CN101151246A (zh) * 2005-03-21 2008-03-26 欧加农股份有限公司 1-苄基吲哚-2-甲酰胺衍生物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DAVID T. CONNOR ET AL.: "Novel Benzothiophene-, Benzofuran-, and Naphthalenecarboxamidotetrazoles as Potential Antiallergy Agents", 《J. MED. CHEM.》 *
MARC NAZARE ET AL.: "Factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of neutral P1 substituents", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *
MARC NAZARE ET AL.: "Probing the Subpockets of Factor Xa Reveals Two Binding Modes for Inhibitors Based on a 2-Carboxyindole Scaffold: A Study Combining Structure-Activity Relationship and X-ray Crystallography", 《J.MED.CHEM.》 *
MICHAEL BRANDS ET AL.: "Novel, selective indole-based ECE inhibitors: Lead optimization via solid-phase and classical synthesis", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *
SUREYYA OLGEN ET AL.: "Synthesis and Antioxidant Properties of Novel N-Substituted Indole-2-carboxamide and Indole-3-acetamide Derivatives", 《ARCH. PHARM. PHARM. MED. CHEM.》 *

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106478662A (zh) * 2012-07-17 2017-03-08 武田药品工业株式会社 5‑ht3受体拮抗剂
US10407443B2 (en) 2012-07-17 2019-09-10 Takeda Pharmaceutical Company Limited 5-HT3 receptor antagonists
US10125145B2 (en) 2012-07-17 2018-11-13 Takeda Pharmaceutical Company Limited 5-HT3 receptor antagonists
CN104854087A (zh) * 2012-12-18 2015-08-19 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的吲哚羧酰胺衍生物
CN104854087B (zh) * 2012-12-18 2017-03-22 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的吲哚羧酰胺衍生物
CN104918946A (zh) * 2013-01-22 2015-09-16 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的杂环酰胺衍生物
US11225478B2 (en) 2013-03-14 2022-01-18 Janssen Pharmaceutica Nv P2X7 modulators
US10150765B2 (en) 2013-03-14 2018-12-11 Janssen Pharmaceutica Nv P2X7 modulators
US9604982B2 (en) 2013-03-14 2017-03-28 Janssen Pharmaceutica Nv P2X7 modulators
CN105209464A (zh) * 2013-03-14 2015-12-30 詹森药业有限公司 P2x7调节剂
US10047092B2 (en) 2013-03-14 2018-08-14 Janssen Pharmaceutica Nv Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
US10053463B2 (en) 2013-03-14 2018-08-21 Janssen Pharmaceutica Nv Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
US10053462B2 (en) 2013-03-14 2018-08-21 Janssen Pharmaceutica Nv P2X7 modulators
US10112937B2 (en) 2013-03-14 2018-10-30 Janssen Pharmaceutica Nv P2X7 modulators and methods of use
US9464084B2 (en) 2013-03-14 2016-10-11 Janssen Pharmaceutica Nv P2X7 modulators
US11820770B2 (en) 2013-03-14 2023-11-21 Janssen Pharmaceutica Nv P2X7 modulators
CN110003200B (zh) * 2013-03-14 2021-11-26 詹森药业有限公司 P2x7调节剂
CN105209464B (zh) * 2013-03-14 2019-01-01 詹森药业有限公司 P2x7调节剂
US10323032B2 (en) 2013-03-14 2019-06-18 Janssen Pharmaceutica Nv P2X7 Modulators
US9540388B2 (en) 2013-03-14 2017-01-10 Janssen Pharmaceutica Nv P2X7 modulators
CN110003200A (zh) * 2013-03-14 2019-07-12 詹森药业有限公司 P2x7调节剂
US10703749B2 (en) 2013-03-14 2020-07-07 Janssen Pharmaceutica Nv P2X7 modulators
CN105636646A (zh) * 2013-07-17 2016-06-01 全球结核病药物研发联盟 氮杂吲哚化合物、其合成及其使用方法
CN105636646B (zh) * 2013-07-17 2017-12-19 全球结核病药物研发联盟 氮杂吲哚化合物、其合成及其使用方法
US10150766B2 (en) 2014-09-12 2018-12-11 Janssen Pharmaceutica Nv P2X7 modulators
US10329306B2 (en) 2014-09-29 2019-06-25 Takeda Pharmaceutical Company Limited Crystalline form of 1-(1-methyl-1H-pyrazol-4-yl)-N-((IR,5S,7S)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1H-indole-3-carboxamide
US11597728B2 (en) 2018-09-28 2023-03-07 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
US11820766B2 (en) 2018-09-28 2023-11-21 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
US11993601B2 (en) 2018-09-28 2024-05-28 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
US11839663B2 (en) 2019-09-30 2023-12-12 Janssen Pharmaceutica Nv Radiolabelled MGL pet ligands
US11891387B2 (en) 2020-03-26 2024-02-06 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
WO2022062991A1 (zh) * 2020-09-22 2022-03-31 苏州恩华生物医药科技有限公司 吲哚衍生物及其应用
WO2023198199A1 (zh) * 2022-04-15 2023-10-19 先声再明医药有限公司 膜缔合酪氨酸和苏氨酸激酶抑制剂

Also Published As

Publication number Publication date
WO2009023623A1 (en) 2009-02-19
EP2185560A1 (en) 2010-05-19
BRPI0812594A2 (pt) 2015-06-23
SG183699A1 (en) 2012-09-27
NZ582056A (en) 2012-08-31
JP2015110566A (ja) 2015-06-18
AU2008286946A1 (en) 2009-02-19
AU2008286946B2 (en) 2013-11-21
EA020332B1 (ru) 2014-10-30
KR20100066422A (ko) 2010-06-17
CA2691512A1 (en) 2009-02-19
CO6251319A2 (es) 2011-02-21
IL202550A0 (en) 2010-06-30
UA99729C2 (en) 2012-09-25
EA200971085A1 (ru) 2010-06-30
JP2010535816A (ja) 2010-11-25
EP2185560A4 (en) 2011-10-05

Similar Documents

Publication Publication Date Title
CN101778850A (zh) 杂芳基酰胺类似物
CN101711245B (zh) 5元杂环酰胺及相关的化合物
CN101772498A (zh) 作为p2x7拮抗剂的杂芳基酰胺类似物
CN101621931A (zh) 杂芳基酰胺衍生物
US20120190680A1 (en) Heteroaryl Amide Analogues
WO2009108551A2 (en) Heteroaryl amide analogues
CN101948425A (zh) 作为糖皮质激素配体的化合物、包含它们的药物组合物、试剂盒及其制备方法
JP2010509224A (ja) ｃｉｓ−シクロヘキシル置換ピリミジノン誘導体
Ihle et al. Heteroaryl amide analogues as P2X7 antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1142599

Country of ref document: HK

C05 Deemed withdrawal (patent law before 1993)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100714